Actively Recruiting
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Led by Changchun BCHT Biotechnology Co. · Updated on 2025-08-08
1650
Participants Needed
1
Research Sites
363 weeks
Total Duration
On this page
Sponsors
C
Changchun BCHT Biotechnology Co.
Lead Sponsor
Y
Yunnan Provincial Center for Disease Control and Prevention
Collaborating Sponsor
AI-Summary
What this Trial Is About
The immunogenicity and safety of the adsorption of cell-free diphtheria and tetanus (three-component) combined vaccine were evaluated at 2 months, 4 months and 6 months.
CONDITIONS
Official Title
Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy infants and young children aged 2 months (60-89 days) who are permanent residents and can provide valid ID for themselves and their legal guardian
- Legal guardian provides informed consent and signs consent form
- Legal guardian can follow the clinical trial protocol requirements
You will not qualify if you...
- History of pertussis, diphtheria, or tetanus
- Contact with someone diagnosed with pertussis or diphtheria in the past 30 days
- Prior vaccination with vaccines containing DTaP components, inactivated poliovirus vaccine, 13-valent pneumococcal conjugate vaccine, or Hib vaccine
- Premature birth before 37 weeks, severe abnormal labor, history of asphyxia rescue, or birth weight less than 2500g
- Axillary temperature above 37.0°C on enrollment day
- Severe congenital malformations, developmental disorders, genetic defects, severe malnutrition, or congenital diseases such as Down syndrome or sickle cell anemia
- History of epilepsy, convulsions, seizures, cerebral palsy, or family history of mental illness
- Autoimmune diseases or immunodeficiencies in the child or immediate family
- Asplenia or splenic dysfunction
- Clinically diagnosed coagulation disorders or bruising that contraindicates intramuscular injection
- History of severe allergic diseases or reactions to vaccines or vaccine components
- Vaccination with subunit or inactivated vaccines within 7 days or live vaccines within 14 days prior
- Receipt of immunoglobulin or blood products (except hepatitis B immunoglobulin) before enrollment
- Immunostimulant or immunosuppressant therapy before enrollment exceeding specified durations or dosages
- Acute moderate or severe illness within 3 days before enrollment
- Use of prophylactic medications within 3 days before enrollment
- Severe clinically diagnosed diseases affecting major body systems or history of malignant tumors
- Current participation or planned participation in other clinical trials during the study period
- Other factors judged by researchers as unsuitable for participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yanshan County Center for Disease Control and Prevention
Wenshan Zhuang and Miao Autonomous Prefecture, Yunnan, China, 663100
Actively Recruiting
Research Team
H
huan xiao li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here